Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis药物敏感结核病患者HIRIF试验中肝毒性的药代动力学和药物基因组学预测因子Clinical Infectious DiseasesIF7.32026-03-060OA
Impact of Pharmacogenetics on Pharmacokinetics of First-Line Antituberculosis Drugs in the HIRIF TrialHIRIF试验中药物基因组学对一线抗结核药物药代动力学的影响JOURNAL OF INFECTIOUS DISEASESIF4.52025-04-170PRE
Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in KazakhstanCLINICAL INFECTIOUS DISEASESIF7.32024-06-041OAAI
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed DrugsCLINICAL INFECTIOUS DISEASESIF7.32023-08-224OAAI
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line DrugsCLINICAL INFECTIOUS DISEASESIF7.32022-03-0425OAAI
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB CohortCLINICAL INFECTIOUS DISEASESIF7.32022-01-1339OAAI
Setting up pharmacovigilance based on available endTB Project data for bedaquilineINTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASEIF3.12020-10-0113OAAI
Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis ReplyAMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINEIF19.42019-05-010OAAI
Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis A Randomized Controlled TrialAMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINEIF19.42018-09-0174OA
Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis (vol 61, e00038-17, 2017)ANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52017-09-010OAAI
Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for TuberculosisANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52017-08-0130OAAI
Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trialBMC INFECTIOUS DISEASESIF32016-08-2735OAAI